AEON Biopharma, Inc. Retained Earnings
AEON Biopharma, Inc. (AEON) had Retained Earnings of -$483.77 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$483.77M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$482.61M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$470.82M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$433.68M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$483.77M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$482.61M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$470.82M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$433.68M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$429.14M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$422.50M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$431.60M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$433.68M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$427.51M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$591.62M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$473.60M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$447.36M 10-Q/A · filed 2024-03-29 | -$423.15M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$11.49M 10-Q · filed 2023-07-21 | |
| 2023-03-31 | -$7.35M 10-Q · filed 2023-05-17 | |
| 2022-12-31 | -$474.84M 10-K/A · filed 2024-05-14 | -$9.47M 10-K · filed 2023-02-22 |
| 2022-09-30 | -$11.58M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$12.40M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$14.19M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$16.96M 10-K/A · filed 2023-04-10 | |
| 2021-09-30 | -$17.21M 10-Q/A · filed 2022-03-03 | |
| 2021-06-30 | -$22.87M 10-Q/A · filed 2022-03-03 | $2.29M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$18.84M 10-Q/A · filed 2022-03-03 | $5.00M 10-Q · filed 2021-06-15 |
| 2021-02-11 | -$667.05K 10-Q · filed 2021-06-15 | |
| 2020-12-31 | -$3.59K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |